Omeros Corp (OMER) Stock Price, Quote & News

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 676 5000

Website: www.omeros.com

Address:

The Omeros Building, 201 Elliott Avenue West, Seattle, United States

Phase3 May. 20 at 7:39 PM

$OMER An army of new buyers ....

2 · Reply

Arad288 May. 20 at 6:49 PM

$OMER we can go down $1.30 a day but not up with the same strength? Let’s go Omer

2 · Reply

Phase3 May. 20 at 5:18 PM

$OMER ........

1 · Reply

uptech May. 20 at 5:18 PM

$OMER I posted that 11 handle entries were about to be history. IMO now the same with 12 handle entries. Act accordingly imo. Look at the market cap and do your homework. The bashers were here for a reason.

1 · Reply

opmankc May. 20 at 5:06 PM

$OMER look like available to borrow shares are rising. avg holding days dropped a tiny weeny bit.. hmm maybe the old biotech shorters are moving somewhere. we are commercialise now its better bet to short someone who hasnt

0 · Reply

MikeLogan May. 20 at 4:51 PM

$OMER

0 · Reply

TRYII May. 20 at 4:28 PM

$OMER Thoughts and Prayers to anyone selling here. Be well.

1 · Reply

Fire7878 May. 20 at 4:24 PM

$OMER i guess we'll see with the next couple of quarters print but based on available guidance not super sexy at 1b valuation. Next quarter estimate 13m. A lot of uncertainty.

0 · Reply

BanaT May. 20 at 4:14 PM

$OMER Did the Jukebox just start playing Hawkshaw Hawkins.. cause were on the Rebound

1 · Reply

Filan May. 20 at 3:48 PM

$OMER for those that have asked, here are my estimates for 2026.

4 · Reply

Omeros Q1 Earnings Call Highlights

May 13, 2026, 4:30 PM EDT - 7 days ago

Omeros Earnings Call Transcript: Q1 2026

May 13, 2026, 4:30 PM EDT - 7 days ago

Omeros Earnings release: Q1 2026

May 13, 2026, 4:30 PM EDT - 7 days ago

Omeros Quarterly report: Q1 2026

2026-05-13T20:27:08.000Z - 7 days ago

Omeros reports Q1 adjusted EPS (24c), consensus (28c)

May 13, 2026, 4:02 PM EDT - 7 days ago

Omeros Corporation Reports First Quarter 2026 Financial Results

2026-05-13T19:54:34.000Z - 7 days ago

Omeros options imply 10.8% move in share price post-earnings

May 11, 2026, 4:02 PM EDT - 9 days ago

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

2026-05-04T12:45:05.000Z - 16 days ago

Kyverna Therapeutics appoints Nadia Dac as chief commercial officer

KYTX

Apr 30, 2026, 8:00 AM EDT - 20 days ago

Omeros Proxy statement: Proxy filing

2026-04-16T14:14:18.000Z - 4 weeks ago

Omeros says CMS assigns permanent reimbursement J-code for YARTEMLEA

Apr 16, 2026, 8:45 AM EDT - 4 weeks ago

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Mar 31, 2026, 4:30 PM EDT - 7 weeks ago

Omeros Earnings Call Transcript: Q4 2025

Mar 31, 2026, 4:30 PM EDT - 7 weeks ago

Omeros Earnings release: Q4 2025

Mar 31, 2026, 4:30 PM EDT - 7 weeks ago

Omeros Annual report: Q4 2025

2026-03-31T20:05:48.000Z - 7 weeks ago

Omeros reports Q4 EPS $1.22, consensus 36c

Mar 31, 2026, 4:02 PM EDT - 7 weeks ago

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Mar 26, 2026, 8:45 AM EDT - 7 weeks ago

Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

Mar 21, 2026, 3:23 AM EDT - 2 months ago

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

2026-02-17T14:15:38.000Z - 3 months ago

Omeros announces completion of nonhuman primates OncotoX-AML study

Feb 17, 2026, 8:45 AM EST - 3 months ago

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

2026-01-27T14:20:24.000Z - 4 months ago

Omeros announces first commercial sales of Yartemlea

Jan 27, 2026, 9:00 AM EST - 4 months ago

Omeros Announces First Commercial Sales of YARTEMLEA®

2026-01-08T11:11:35.000Z - 4 months ago

Omeros price target raised to $40 from $20 at H.C. Wainwright

Jan 7, 2026, 6:50 PM EST - 4 months ago

Omeros prices transplant complication drug at $36,000 per dose

Jan 7, 2026, 4:30 PM EST - 4 months ago

Omeros Transcript: FDA Announcement

Jan 7, 2026, 4:30 PM EST - 4 months ago

Omeros Press release: FDA Announcement

2025-12-30T15:45:11.000Z - 5 months ago

Omeros call volume above normal and directionally bullish

2025-12-29T16:45:08.000Z - 5 months ago

Omeros call volume above normal and directionally bullish

Dec 26, 2025, 6:36 PM EST - 5 months ago

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

2025-12-24T15:55:07.000Z - 5 months ago

D. Boral Capital notes Omeros’ YARTEMLEA FDA win, maintains Buy rating

2025-12-24T15:30:10.000Z - 5 months ago

H.C. Wainwright says Yartemlea approval ‘significant validation’ of Omeros value

2025-12-24T15:15:15.000Z - 5 months ago

Omeros trading resumes

2025-12-24T15:10:19.000Z - 5 months ago

Omeros trading halted, volatility trading pause

2025-12-24T15:10:08.000Z - 5 months ago

Omeros up 100% at $17.55 upon resumption of trading

2025-12-24T14:40:42.000Z - 5 months ago

Omeros to resume trading at 9:50 am ET

2025-12-24T14:05:07.000Z - 5 months ago

Omeros announces FDA approved YARTEMLE for treatment of TA-TMA

Dec 24, 2025, 9:05 AM EST - 5 months ago

US FDA approves Omeros' drug to treat dangerous transplant complication

Dec 24, 2025, 9:00 AM EST - 5 months ago

FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

2025-12-24T11:45:14.000Z - 5 months ago

Omeros trading halted, news pending

Dec 1, 2025, 8:30 AM EST - 6 months ago

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Nov 13, 2025, 4:30 PM EST - 6 months ago

Omeros Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 6 months ago

Omeros Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 6 months ago

Omeros Earnings release: Q3 2025

Nov 13, 2025, 4:11 PM EST - 6 months ago

Omeros Corporation Reports Third Quarter 2025 Financial Results

Nov 11, 2025, 8:30 AM EST - 6 months ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Oct 23, 2025, 8:17 AM EDT - 7 months ago

Breakout Momentum Plays You Need to Know About

QURE SDST

Oct 16, 2025, 8:30 AM EDT - 7 months ago

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Oct 15, 2025, 11:54 AM EDT - 7 months ago

Can OMER stock retain Novo Nordisk driven gains over the long-term?

Oct 15, 2025, 9:17 AM EDT - 7 months ago

Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug

NVO

Oct 15, 2025, 8:32 AM EDT - 7 months ago

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

NVO

Oct 15, 2025, 8:30 AM EDT - 7 months ago

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Sep 2, 2025, 8:45 AM EDT - 9 months ago

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Aug 14, 2025, 4:30 PM EDT - 9 months ago

Omeros Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 9 months ago

Omeros Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 9 months ago

Omeros Earnings release: Q2 2025

Aug 14, 2025, 4:02 PM EDT - 9 months ago

Omeros Corporation Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:02 PM EDT - 10 months ago

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Jul 25, 2025, 8:00 AM EDT - 10 months ago

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Jun 27, 2025, 8:30 AM EDT - 11 months ago

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Jun 24, 2025, 8:30 AM EDT - 11 months ago

Omeros Announces Webcast Details for Annual Meeting of Shareholders

May 30, 2025, 8:00 AM EDT - 1 year ago

Omeros Proxy statement: Proxy Filing

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Quarterly report: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q1 2025

May 15, 2025, 4:05 PM EDT - 1 year ago

Omeros Corporation Reports First Quarter 2025 Financial Results

May 12, 2025, 5:05 PM EDT - 1 year ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

May 12, 2025, 10:35 AM EDT - 1 year ago

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

May 6, 2025, 9:16 AM EDT - 1 year ago

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

Apr 10, 2025, 9:10 AM EDT - 1 year ago

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Apr 8, 2025, 9:00 AM EDT - 1 year ago

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q4 2024

Mar 31, 2025, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Mar 26, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Mar 21, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Feb 20, 2025, 9:10 AM EST - 1 year ago

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Feb 14, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Feb 10, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Jan 16, 2025, 9:15 AM EST - 1 year ago

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Dec 19, 2024, 9:15 AM EST - 1 year ago

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Dec 10, 2024, 8:45 AM EST - 1 year ago

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Dec 2, 2024, 8:45 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Nov 21, 2024, 9:15 AM EST - 1 year ago

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Nov 13, 2024, 4:30 PM EST - 1 year ago

Omeros Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Omeros Earnings release: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Omeros Quarterly report: Q3 2024

Nov 13, 2024, 4:02 PM EST - 1 year ago

Omeros Corporation Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 4:11 PM EST - 1 year ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

Oct 24, 2024, 8:45 AM EDT - 1 year ago

FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Omeros Quarterly report: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q2 2024

Aug 7, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Second Quarter 2024 Financial Results

Aug 5, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024

Phase3 May. 20 at 7:39 PM

$OMER An army of new buyers ....

2 · Reply

Arad288 May. 20 at 6:49 PM

$OMER we can go down $1.30 a day but not up with the same strength? Let’s go Omer

2 · Reply

Phase3 May. 20 at 5:18 PM

$OMER ........

1 · Reply

uptech May. 20 at 5:18 PM

1 · Reply

opmankc May. 20 at 5:06 PM

0 · Reply

MikeLogan May. 20 at 4:51 PM

$OMER

0 · Reply

TRYII May. 20 at 4:28 PM

$OMER Thoughts and Prayers to anyone selling here. Be well.

1 · Reply

Fire7878 May. 20 at 4:24 PM

$OMER i guess we'll see with the next couple of quarters print but based on available guidance not super sexy at 1b valuation. Next quarter estimate 13m. A lot of uncertainty.

0 · Reply

BanaT May. 20 at 4:14 PM

$OMER Did the Jukebox just start playing Hawkshaw Hawkins.. cause were on the Rebound

1 · Reply

Filan May. 20 at 3:48 PM

$OMER for those that have asked, here are my estimates for 2026.

4 · Reply

UnrealMachine May. 20 at 2:55 PM

$OMER next quarter 3 full months of sales - $30M? Any other guesses?

4 · Reply

Dragan7 May. 20 at 1:53 PM

$OMER ASCO will start next week.

0 · Reply

opmankc May. 20 at 1:38 PM

$OMER getting real exited

0 · Reply

jacksparo May. 20 at 1:20 PM

$AKBA Seriously some people not suited for the market. I brought bad luck for what?!!! Did you ever check $SLS $IBRX $CAPR $OMER I am going to block the nonsense . Stop tagging my name .

1 · Reply

bombastic_ May. 20 at 12:05 PM

$OMER patience. Big payoffs. Time is not an issue for me

0 · Reply

opmankc May. 20 at 11:16 AM

$OMER 👀 so am i getting the chance to buy at 10 or not?

1 · Reply

Dollarsforboats May. 20 at 3:27 AM

$OMER https://link.springer.com/article/10.1007/s40265-026-02328-8

0 · Reply

uptech May. 19 at 11:34 PM

$OMER 11 handle entries about to go extinct. Hope you got some.

0 · Reply

costrexx May. 19 at 9:15 PM

$OMER first time this has happened since using etrade. It’s an easy pick at these prices. I nibbled a little today when it went below the price of the buyback

1 · Reply

Niuniucat May. 19 at 8:32 PM

$OMER greg owns 5.8 millions shares about 7.7% according to share holder book ?

2 · Reply

MinnieSteve3 May. 19 at 8:01 PM

$OMER Nice EOD rally.

1 · Reply

UnrealMachine May. 19 at 5:33 PM

$OMER would love to see that 100m milestone land soon with much of it devoted to Buybacks. Greg - we have been patient - we deserve it!!! Buyback prior to EU approval and the SP moving up plz

2 · Reply

Market Cap	846.79M
Revenue (ttm)	0.00
Net Income (ttm)	-3.35M
EPS (ttm)	N/A
PE Ratio	5.62
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-2.16

Volume	1,052,156
Avg Vol	1,235,060
Day's Range	N/A - N/A
Shares Out	72.38M
Stochastic %K	16%
Beta	2.66
Analysts	Strong Sell
Price Target	$43.67